# Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected

> **NCT06613789** · PHASE1 · NOT_YET_RECRUITING · sponsor: **HIV Vaccine Trials Network** · enrollment: 22 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** 426c.Mod.Core-C4b
- **BIOLOGICAL:** 3M-052-AF
- **BIOLOGICAL:** Aluminum hydroxide suspension (Alum)
- **BIOLOGICAL:** Placebo and Diluent

## Key facts

- **NCT ID:** NCT06613789
- **Lead sponsor:** HIV Vaccine Trials Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-13
- **Primary completion:** 2027-06-03
- **Final completion:** 2027-06-03
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2025-12-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06613789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06613789, "Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06613789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*